Literature DB >> 10994724

In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652.

R V Parsey1, L S Kegeles, D R Hwang, N Simpson, A Abi-Dargham, O Mawlawi, M Slifstein, R L Van Heertum, J J Mann, M Laruelle.   

Abstract

UNLABELLED: Abnormal brain regional densities of serotonin (5-hydroxytryptamine [5-HT]) transporters have been reported in postmortem studies in several neuropsychiatric conditions, such as major depression and schizophrenia. trans-1,2,3,5,6,10-beta-Hexahydro-6-[4-(methylthio)phenyl]pyrrolo-[2,1-a]-isoquinoline ([11C]McN 5652) is the first PET radioligand successfully developed to label 5-HT transporters in the living human brain. The purpose of this study was to develop an imaging protocol and analytic method to measure regional 5-HT transporter binding potential (BP) with [11C]McN 5652 in humans.
METHODS: The arterial input function and brain uptake of (+)-[11C]McN 5652 and (-)-[11C]McN 5652, the active and inactive enantiomers, respectively, were measured in 6 healthy volunteers.
RESULTS: (+)-[11C]McN 5652 concentrated in brain regions rich in 5-HT transporters (midbrain, thalamus, basal ganglia, and medial temporal lobe structures), whereas the uptake of (-)-[11C]McN 5652 was more uniformly distributed. Total distribution volumes (V(T)) were derived using kinetic 2-compartment analysis and graphic analysis. V(T) derived by both methods were highly correlated. (+)-[11C]McN 5652 regional V(T) ranged from 18 +/- 2 mL/g in the cerebellum to 46 +/- 13 mL/g in the midbrain. (-)-[11C]McN 5652 regional VT ranged from 10 +/- 2 mL/g in the cerebellum to 14 +/- 3 mL/g in the thalamus. (+)-[11C]McN 5652 V(T) were higher than (-)-[11C]McN 5652 V(T) in all regions, including the cerebellum, a region devoid of 5-HT transporters. Blocking experiments were also performed in baboons with saturating doses of citalopram and in humans with nonsaturating doses of paroxetine. Cerebellar and neocortical (+)-[11C]McN 5652 V(T) were unaffected by pretreatment with 5-HT transporter blockers. In areas of high receptor concentration (midbrain, caudate, and thalamus) 5-HT transporter blockers decreased (+)-[11C]McN 5652 V(T) to the level of cerebellum (+)-[11C]McN 5652 V(T).
CONCLUSION: These experiments indicate that the use of the difference between (+)- and (-)-[11C]McN 5652 V(T) to define specific binding to 5-HT transporters leads to an overestimation of specific binding. 5-HT transporter BP was derived as the difference between the regional and cerebellar (+)-[11C]McN 5652 V(T). BP values were in good agreement with the distribution of 5-HT transporters in the human brain, except for regions of relatively low 5-HT transporter concentration, such as the prefrontal cortex, where no specific binding was detected using (+)-[11C]McN 5652. (+)-[11C]McN 5652 is an appropriate radiotracer to quantify 5-HT transporters in regions with relatively high concentration of 5-HT transporters, such as the midbrain, thalamus, and basal ganglia, and should prove useful in elucidating abnormalities of 5-HT transmission in neuropsychiatric conditions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10994724

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  23 in total

1.  The 5-HT(2A) receptor and serotonin transporter in Asperger's disorder: A PET study with [¹¹C]MDL 100907 and [¹¹C]DASB.

Authors:  Ragy R Girgis; Mark Slifstein; Xiaoyan Xu; W Gordon Frankle; Evdokia Anagnostou; Stacey Wasserman; Lauren Pepa; Alexander Kolevzon; Anissa Abi-Dargham; Marc Laruelle; Eric Hollander
Journal:  Psychiatry Res       Date:  2011-11-12       Impact factor: 3.222

2.  In vivo variation in metabotropic glutamate receptor subtype 5 binding using positron emission tomography and [11C]ABP688.

Authors:  Christine DeLorenzo; J S Dileep Kumar; J John Mann; Ramin V Parsey
Journal:  J Cereb Blood Flow Metab       Date:  2011-07-27       Impact factor: 6.200

3.  Imaging of the brain serotonin transporters (SERT) with 18F-labelled fluoromethyl-McN5652 and PET in humans.

Authors:  Swen Hesse; Peter Brust; Peter Mäding; Georg-Alexander Becker; Marianne Patt; Anita Seese; Dietlind Sorger; Jörg Zessin; Philipp M Meyer; Donald Lobsien; Sven Laudi; Bernd Habermann; Frank Füchtner; Julia Luthardt; Anke Bresch; Jörg Steinbach; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-17       Impact factor: 9.236

4.  Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users.

Authors:  Ralph Buchert; Rainer Thomasius; Kay Petersen; Florian Wilke; Jost Obrocki; Bruno Nebeling; Lutz Wartberg; Pavlina Zapletalova; Malte Clausen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-17       Impact factor: 9.236

5.  Lack of association between the serotonin transporter and serotonin 1A receptor: an in vivo PET imaging study in healthy adults.

Authors:  Michael Strupp-Levitsky; Jeffrey M Miller; Harry Rubin-Falcone; Francesca Zanderigo; Matthew S Milak; Gregory Sullivan; R Todd Ogden; Maria A Oquendo; Christine DeLorenzo; Norman Simpson; Ramin V Parsey; J John Mann
Journal:  Psychiatry Res Neuroimaging       Date:  2016-08-08       Impact factor: 2.376

6.  Synthesis, radiolabeling and baboon SPECT imaging of 2beta-carbomethoxy-3beta-(3'-[(123)I]iodophenyl)tropane ([(123)I]YP256) as a serotonin transporter radiotracer.

Authors:  Frederic Bois; Ronald M Baldwin; Louis Amici; Mohammed S Al-Tikriti; Nora Kula; Ross Baldessarini; Robert B Innis; Julie K Staley; Gilles D Tamagnan
Journal:  Nucl Med Biol       Date:  2008-01       Impact factor: 2.408

7.  Reported childhood abuse is associated with low serotonin transporter binding in vivo in major depressive disorder.

Authors:  Jeffrey M Miller; Erin L Kinnally; R Todd Ogden; Maria A Oquendo; J John Mann; Ramin V Parsey
Journal:  Synapse       Date:  2009-07       Impact factor: 2.562

8.  Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa.

Authors:  Ursula F Bailer; Guido K Frank; Julie C Price; Carolyn C Meltzer; Carl Becker; Chester A Mathis; Angela Wagner; Nicole C Barbarich-Marsteller; Cinnamon S Bloss; Karen Putnam; Nicholas J Schork; Anthony Gamst; Walter H Kaye
Journal:  Psychiatry Res       Date:  2012-11-13       Impact factor: 3.222

9.  Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography.

Authors:  Maria A Oquendo; Ramin S Hastings; Yung-Yu Huang; Norman Simpson; R Todd Ogden; Xian-Zhang Hu; David Goldman; Victoria Arango; Ronald L Van Heertum; J John Mann; Ramin V Parsey
Journal:  Arch Gen Psychiatry       Date:  2007-02

10.  Serotonin transporter binding as a possible predictor of one-year remission in major depressive disorder.

Authors:  Jeffrey M Miller; Maria A Oquendo; R Todd Ogden; J John Mann; Ramin V Parsey
Journal:  J Psychiatr Res       Date:  2008-03-10       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.